Gabapentin and Risk of Pancreatic Cancer and Renal Cancer

March 29, 2011

The focus of this clinical trial was evaluate how exposure to gabapentin increased a patient's risk of developing pancreatic or renal cancers.

Study Type: Observational

Age/Gender Requirements: Not listed

Sponsor: GlaxoSmithKline

Purpose: The main objective of this clinical trial was "to determine whether exposure to gabapentin is associated with an increased risk of dveloping pancreatic cancer or renal cancer in the United Kingdom (UK) General Practice Research Database (GPRD)."

ClinicalTrials.gove identifier: NCT01138124

Click here to access additional information about the clinical trial.